About Us

Bharat Immuno Therapeutics is a HealthTech company developing two complementary AI-powered precision medicine platforms—AiResolve and AiDiscover—designed to transform complex clinical, molecular, and immune data into actionable intelligence for patient care and therapeutic development.

AiResolve is a Predictive Immune Intelligence and Precision Medicine Platform that integrates clinical and longitudinal patient data with multimodal and immune profiling, supported by explainable AI. It is designed to enable earlier risk prediction, patient stratification, personalized disease and treatment-response assessment, and longitudinal immune monitoring. AiResolve is being developed for secure integration with existing hospital and clinical data environments.

AiDiscover is a Precision Drug Discovery and Translational Intelligence Platform that uses AI, computational biology, multi-omics, and human disease data to uncover disease mechanisms, identify and prioritize therapeutic targets, discover drug-repurposing and combination opportunities, understand treatment resistance, and support the development of new therapeutic strategies. Its translational pathway is: Right Biology → Right Target → Right Drug → Right Patient → Right Trial.

The company's initial clinical focus is Hematology, Cell Therapy, and Oncology, particularly stem cell/bone marrow transplantation, graft-versus-host disease (GVHD), CAR-T therapy, and cancer. From this focused entry point, the two platforms are designed to expand across immuno-oncology, autoimmune and chronic inflammatory diseases, and solid-organ transplantation, creating a connected precision-medicine ecosystem spanning patient stratification and clinical decision intelligence through AiResolve, and biomarker, target, and therapeutic discovery through AiDiscover.

Our Platforms

Two Complementary Precision Medicine Platforms

Bharat Immuno Therapeutics brings together patient-centric clinical intelligence and disease-centric drug discovery through two connected platforms designed to support the full precision-medicine continuum.

AiResolve

Predictive Immune Intelligence & Precision Medicine

For hospitals, clinicians and clinical research teams. AiResolve focuses on early risk prediction, patient stratification, treatment-response assessment and longitudinal immune monitoring using clinical, molecular and multi-omics data.

Explore AiResolve →

AiDiscover

Precision Drug Discovery & Translational Intelligence

For pharma, biotech and research partners. AiDiscover focuses on disease mechanisms, biomarkers, target discovery, drug repurposing, rational combinations and resistance biology to support therapeutic development.

Explore AiDiscover →
AiResolve Platform

From Complex Patient Data to Actionable Clinical Insight

AiResolve combines clinical and longitudinal data with multimodal and immune profiling, then applies explainable AI to generate patient-specific insights for risk assessment, biomarker discovery, treatment-response evaluation, and longitudinal monitoring.

Patient & Biological Inputs

Clinical & longitudinal data
Genomic & transcriptomic profiling
Immune & cellular profiling
Proteomic & metabolomic data

AiResolve

Predictive Immune Intelligence & Precision Medicine Engine
Multimodal Integration Explainable AI Immune Intelligence Patient-specific Models

Clinical & Translational Outputs

Early risk prediction
Biomarker discovery
Patient stratification
Treatment & monitoring insights
01
CollectClinical and molecular data
02
ProfileGenerate multimodal immune profiles
03
IntegrateUnify biological and clinical signals
04
InterpretExplainable predictive intelligence
05
Act & MonitorPersonalized insights over time
AiDiscover Platform

Precision Drug Discovery from Human Biology

AiDiscover is Bharat Immuno's disease-centric precision drug discovery platform. It integrates multi-omics, clinical and immune data with AI-driven computational biology to uncover disease mechanisms, prioritize therapeutic targets, identify repurposing and combination opportunities, and advance experimentally testable therapeutic hypotheses.

Right BiologyDefine disease mechanisms and molecular endotypes
Right TargetPrioritize biomarkers, pathways and therapeutic targets
Right DrugRank candidates, repurposing and rational combinations
Right PatientConnect molecular signatures with responder biology
Right TrialGenerate translational hypotheses for validation and development

Disease-Mechanism Discovery

Identifies molecular endotypes, dysregulated pathways and biological drivers using integrated clinical and multi-omics evidence.

Therapeutic Target Prioritization

Ranks actionable targets and biomarkers using computational evidence, immune context and disease relevance.

Drug Repurposing & Combinations

Explores existing drugs and rational combinations that may address identified mechanisms or resistance pathways.

Resistance Biology

Investigates why patients fail or relapse after therapy and identifies pathways that may support next-generation strategies.

Experimental Translation

Prioritizes therapeutic hypotheses for functional assays, preclinical validation and candidate development.

Pharma & Biotech Intelligence

Supports biomarker-led translational research, patient stratification, target discovery and clinical-development decisions.

AiDiscover: Right Biology → Right Target → Right Drug → Right Patient → Right Trial

Our Team

AiResolve is led by a world-class team of scientists, clinicians, and entrepreneurs with expertise in computational biology, immunology, clinical dermatology, and biotech strategy. Together, we bridge science and business to bring transformative diagnostics to patients worldwide.

Dr. Ram Vinay Pandey
Dr. Ram Vinay Pandey, PhD

Founder & CEO

Dr. Hanna Knaus, M.D., Ph.D.
Dr. Hanna Knaus, M.D., Ph.D.

Clinical Lead & GVHD expert

Dr. Lusia Unterluggauer
Dr. Lusia Unterluggauer

Clinical Scientist

Dr. Anand Kant Das, PhD
Dr. Anand Kant Das, PhD

Business Lead, Abu Dhabi, UAE

Radha Raman Pandey
Radha Raman Pandey, MBA

Business Development Manager, New Delhi, India

Dr. Arunabh Ray
Dr. Arunabh Ray

Chief Operating Officer, New Delhi, India

Prof. george
Prof. George Stary, MD, PhD

Co-founder & CSO

Jaishree Singh
Jaishree Singh

CIO & AI/ML Expert, Vienna

Dr. Rabindranath Paul, PhD
Dr. Rabindranath Paul, PhD

Scientific Lead, Abu Dhabi, UAE

Swathi dutt
Swathi Dutt

AI Strategist – Bioinformatics, Vienna

Dr. Sujay Shivaji Patil
Dr. Sujay Shivaji Patil

Chief Scientific Officer, Mumbai, India

Amit Kumar Chauhan
Amit Kumar Chauhan

Strategy and Funding Manager, New Delhi, India

Dr. Priyanka Dutta
Dr. Priyanka Dutta Passecker, MBA, PhD

Business Development Expert

Juraj Hunák, MSc (WU)
Juraj Hunák, MSc (WU)

Chief Financial Officer (CFO)

Laura Maria Gail
Laura Maria Gail

Immunologist

Nishant Kumar Verma
Nishant Kumar Verma

CTO & AI/ML Expert, Vienna

Suresh Desai
Suresh Desai

Business Lead, Mumbai, India

Advisory Board

From Vision to Validation—Strategic Guidance Backed by Decades of Success

Prof. Werner Rabitsch
Prof. Werner Rabitsch

Stem Cell Transplant Expert

Prof. Yenan Bryceson
Prof. Yenan Bryceson

Cancer Immunologist

Dr. André Rendeiro
Dr. André Rendeiro

Computational Biology/AI Expert

Prof. Robert Zeiser
Prof. Robert Zeiser

Hematologist, Oncologist

Prof. Hildegard Greinix
Prof. Hildegard Greinix

GVHD Expert

Dr. Andreas Weinhäusel
Dr. Andreas Weinhäusel

Molecular Diagnostics Expert

Martin Rudolf, BS IBA
Martin Rudolf, BS IBA

Business Development Advisor

Dr. Marc J. Brehme
Dr. Marc J. Brehme, MBA

Strategy & Fundraising Advisor

Florian Glatt-Wodzyński
Florian Glatt-Wodzyński

Business & Regulatory Advisor

Martin Rudolf, BS IBA
Gaurav Gandhi

Strategic Advisor, Austria, India

Dr. Constance Ciaudo Beyer, PhD
Dr. Constance Ciaudo Beyer, PhD

Senior Investment Advisor

Zurich, Switzerland

Our Strategic Partners

Collaborating with world-renowned institutions to advance precision medicine and transform healthcare.

Medical University of Vienna | Visit Website →

One of Europe's leading academic health centers, closely affiliated with Vienna General Hospital (AKH Wien) for access to highly specialized departments and digitalized clinical environments.

  • Practical validation of hospital IT integration
  • Standards-driven evolution of the MVP
  • Early clinical feedback to increase market readiness
Medical University of Graz | Visit Website →

A leading hub for biomedical research and digital health in Central Europe, integrated with LKH-Univ. Klinikum Graz for system-level testing and validation.

  • Access to structured clinical datasets
  • Real-world validation insights
  • Strengthened credibility with stakeholders
Karolinska Institutet, Stockholm | Visit Website →

A global pioneer in translational medicine and digital health innovation, bridging cutting-edge clinical research with large-scale deployment of AI and healthcare technologies.

  • Trusted medical data standards (e.g., SNOMED CT, FHIR)
  • Early validation in real-world clinical settings
  • International credibility and recognition
CeMM Research Centre | Visit Website →

CeMM is a leading European institute at the intersection of biomedicine, systems biology, and precision medicine — embedded within the clinical ecosystem of Vienna General Hospital (AKH).

Austrian Institute of Technology (AIT) | Visit Website →

Austria's premier applied research center for digital health and clinical decision support — supporting MDR/EU AI Act alignment, clinical algorithms, and real-world deployment.

Prognica Labs | Visit Website →

Accelerating drug discovery from molecule to medicine through autonomous AI agents and computational platforms.

  • 10× faster discovery via AI automation
  • Lower early-stage costs through in-silico evaluation
  • Reduced clinical risk using digital twin simulations

Publications

Our team has published extensively in top-tier journals such as Science, Immunity, and Journal of Experimental Medicine, advancing the fields of computational immunology, Oncology, GVHD research, and precision diagnostics.

  1. Strobl J, Gail LM, Krecu L, Madad S, Kleissl L, Unterluggauer L, Redl A, Brazdilova K, Saluzzo S, Wohlfarth P, Knaus HA, Mitterbauer M, Rabitsch W, Haniffa M, Stary G. Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease. Br J Dermatol. 2024 Feb 16;190(3):402-414.
    DOI: 10.1093/bjd/ljad402 | PMID: 38010706 | PMCID: PMC10873647.

  2. Pandey RV, Strobl J, Redl A, Unterluggauer L, Gail L, Kleissl L, Müller S, Atzmüller D, Fife-Gernedl V, Krausgruber T, Knaus H, Mitterbauer M, Wohlfarth P, Rabitsch W, Bock C, Stary G. Epigenetic regulation of T cell lineages in skin and blood following hematopoietic stem cell transplantation. Clin Immunol. 2023 Mar;248:109245.
    DOI: 10.1016/j.clim.2023.109245 | PMID: 36702179.

  3. Strobl J, Gail LM, Kleissl L, Pandey RV, Smejkal V, Huber J, Puxkandl V, Unterluggauer L, Dingelmaier-Hovorka R, Atzmüller D, Krausgruber T, Bock C, Wohlfarth P, Rabitsch W, Stary G. Human resident memory T cells exit the skin and mediate systemic Th2-driven inflammation. J Exp Med. 2021 Nov 1;218(11):e20210417.
    DOI: 10.1084/jem.20210417 | PMID: 34643646 | PMCID: PMC8563284.

  4. Strobl J, Pandey RV, Krausgruber T, Bayer N, Kleissl L, Reininger B, Vieyra-Garcia P, Wolf P, Jentus MM, Mitterbauer M, Wohlfarth P, Rabitsch W, Stingl G, Bock C, Stary G. Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease. Sci Transl Med. 2020 Nov 18;12(570):eabb7028.
    DOI: 10.1126/scitranslmed.abb7028 | PMID: 33208504 | PMCID: PMC7615006.

  5. Strobl J, Pandey RV, Krausgruber T, Kleissl L, Reininger B, Herac M, Bayer N, Krall C, Wohlfarth P, Mitterbauer M, Kalhs P, Rabitsch W, Bock C, Hopfinger G, Stary G. Anti-Apoptotic Molecule BCL2 Is a Therapeutic Target in Steroid-Refractory Graft-Versus-Host Disease. J Invest Dermatol. 2020 Nov;140(11):2188-2198.
    DOI: 10.1016/j.jid.2020.02.029 | PMID: 32247860.

  6. Lim CX, Redl A, Kleissl L, Pandey RV, Mayerhofer C, El Jammal T, Mazic M, Gonzales K, Sukhbaatar N, Krausgruber T, Bock C, Hengstschläger M, Calender A, Pacheco Y, Stary G, Weichhart T. Aberrant Lipid Metabolism in Macrophages Is Associated with Granuloma Formation in Sarcoidosis. Am J Respir Crit Care Med. 2024 May 1;209(9):1152-1164.
    DOI: 10.1164/rccm.202307-1273OC | PMID: 38353578 | PMCID: PMC7617514.

  7. Zitti B, Hoffer E, Zheng W, Pandey RV, Schlums H, Perinetti Casoni G, Fusi I, Nguyen L, Kärner J, Kokkinou E, Carrasco A, Gahm J, Ehrström M, Happaniemi S, Keita ÅV, Hedin CRH, Mjösberg J, Eidsmo L, Bryceson YT. Human skin-resident CD8+ T cells require RUNX2 and RUNX3 for induction of cytotoxicity and expression of the integrin CD49a. Immunity. 2023 Jun 13;56(6):1285-1302.e7.
    DOI: 10.1016/j.immuni.2023.05.003 | PMID: 37269830.

  8. Kokkinou E, Soini T, Pandey RV, van Acker A, Theorell J, Czarnewski P, Kvedaraite E, Vandamme N, Lourda M, Sorini C, Weigel W, Carrasco A, Tibbitt CA, Schlums H, Lindforss U, Nordenvall C, Ljunggren M, Ideström M, Svensson M, Henter JI, Villablanca EJ, Bryceson YT, Rolandsdotter H, Mjösberg J. The single-cell transcriptional landscape of innate and adaptive lymphocytes in pediatric-onset colitis. Cell Rep Med. 2023 May 16;4(5):101038.
    DOI: 10.1016/j.xcrm.2023.101038 | PMID: 37160121 | PMCID: PMC10213874.

  9. Stary V, Pandey RV, List J, Kleissl L, Deckert F, Kabiljo J, Laengle J, Gerakopoulos V, Oehler R, Watzke L, Farlik M, Lukowski SW, Vogt AB, Stary G, Stockinger H, Bergmann M, Pilat N. Dysfunctional tumor-infiltrating Vδ1+ T lymphocytes in microsatellite-stable colorectal cancer. Nat Commun. 2024 Aug 13;15(1):6949.
    DOI: 10.1038/s41467-024-51025-1 | PMID: 39138181 | PMCID: PMC11322529.

Contact Us

Connect with our European and Indian teams for clinical collaborations, research partnerships, technology deployment, and strategic opportunities around AiResolve and AiDiscover.

Austria

NextGen Immuno Therapeutics
Dr. Ram Vinay Pandey, PhD
Founder & CEO
Nippongasse 8, 1220 Vienna, Austria
ramvinay.pandey@nextgenimmuno.com
office@nextgenimmuno.com
+43 6507276982
www.nextgenimmuno.com

India

Bharat Immuno Private Limited
Dr. Ram Vinay Pandey, PhD
Founder & CEO
Neb Sarai, H/NO. 29 New Delhi-110068, India
ramvinay.pandey@bharatimmuno.com
office@bharatimmuno.com
+91 99994 04163
www.bharatimmuno.com